Agilent Technologies Inc. (Santa Clara, California) and Seahorse Bioscience (Billerica, Massachusetts) have signed a definitive agreement under which Agilent will acquire Seahorse Bioscience, a provider of instruments and assay kits for measuring cell metabolism and bioenergetics.
Agilent Technologies Inc. (Santa Clara, California) and Seahorse Bioscience (Billerica, Massachusetts) have signed a definitive agreement under which Agilent will acquire Seahorse Bioscience, a provider of instruments and assay kits for measuring cell metabolism and bioenergetics.
Seahorse Bioscience’s technology enables researchers to better understand cell health, function, and signaling, and how the cell may be impacted by the introduction of a specific drug, by providing real-time kinetics to unlock essential bioenergetics data.
Scientists use Seahorse Bioscience’s proprietary XF Technology to research the roll of cell metabolism in neurodegeneration, aging, cancer, cardiovascular disease cell physiology, toxicology, and hepatobiology, immunology, infectious diseases, mitochondrial diseases, model organisms, obesity, diabetes, metabolic disorders, screening, and translational medicine.
Distinguishing Alcohol- from Non-Alcohol-Associated Liver Cirrhosis with LC-MS
May 7th 2025A pilot study investigating whether nicotinamide adenine dinucleotide kinase (NADK) expression is selectively diminished in alcohol-associated liver cirrhosis (AC), as well as evaluating its potential as a biomarker for this condition, measured AC and non-AC (NAC). Nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+) levels in human liver samples were measured using liquid chromatography-mass spectrometry (LC-MS).